Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 20, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $98.84 to $10,479,200.00.

Highlighted Stocks Traded by Insiders:

Flowserve (FLS) - FREE Research Report

Blinn Mark A, who is President & CEO at Flowserve, sold 69,000 shares at $62.48 on Feb. 20, 2015. Following this transaction, the President & CEO owned 141,574 shares meaning that the stake was reduced by 32.77% with the 69,000-share transaction.

Pajonas Thomas L, who is SVP, Chief Operating Officer at Flowserve, sold 40,000 shares at $62.48 on Feb. 20, 2015. Following this transaction, the SVP, Chief Operating Officer owned 52,990 shares meaning that the stake was reduced by 43.02% with the 40,000-share transaction.

Taff Michael S, who is SVP and CFO at Flowserve, sold 30,000 shares at $62.48 on Feb. 20, 2015. Following this transaction, the SVP and CFO owned 32,102 shares meaning that the stake was reduced by 48.31% with the 30,000-share transaction.

The shares most recently traded at $62.24, down $0.24, or 0.39% since the insider transaction. Historical insider transactions for Flowserve go as follows:

  • 4-Week # shares sold: 2,232
  • 12-Week # shares sold: 2,232
  • 24-Week # shares sold: 2,232

The average volume for Flowserve has been 1.9 million shares per day over the past 30 days. Flowserve has a market cap of $8.4 billion and is part of the industrial goods sector and industrial industry. Shares are up 4.55% year-to-date as of the close of trading on Friday.

Flowserve Corporation designs, manufactures, distributes, and services industrial flow management equipment. The stock currently has a dividend yield of 1.15%. The company has a P/E ratio of 16.6. Currently, there are 9 analysts who rate Flowserve a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLS - FREE

TheStreet Quant Ratings

rates Flowserve as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Flowserve Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Fleetcor Technologies (FLT) - FREE Research Report

Johnson Mark A, who is Director at Fleetcor Technologies, sold 15,000 shares at $152.62 on Feb. 20, 2015. Following this transaction, the Director owned 116,600 shares meaning that the stake was reduced by 11.4% with the 15,000-share transaction.

The shares most recently traded at $154.98, up $2.36, or 1.52% since the insider transaction. Historical insider transactions for Fleetcor Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 9,280
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 9,280
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 9,280

The average volume for Fleetcor Technologies has been 753,700 shares per day over the past 30 days. Fleetcor Technologies has a market cap of $12.9 billion and is part of the services sector and diversified services industry. Shares are up 5.2% year-to-date as of the close of trading on Friday.

FleetCor Technologies, Inc. provides fuel cards and workforce payment products and services in North America, Latin America, Europe, Australia, and New Zealand. The company has a P/E ratio of 29.9. Currently, there are 4 analysts who rate Fleetcor Technologies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLT - FREE

TheStreet Quant Ratings

rates Fleetcor Technologies as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, good cash flow from operations, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Fleetcor Technologies Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NxStage Medical (NXTM) - FREE Research Report

Swan Winifred L, who is SVP and General Counsel at NxStage Medical, sold 500 shares at $17.60 on Feb. 20, 2015. Following this transaction, the SVP and General Counsel owned 17,688 shares meaning that the stake was reduced by 2.75% with the 500-share transaction.

The shares most recently traded at $17.57, down $0.03, or 0.17% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 15,500
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 46,897

The average volume for NxStage Medical has been 359,800 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 0.89% year-to-date as of the close of trading on Friday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null